Key result
Adding cardiac rehabilitation to sacubitril/valsartan boosts VO2 peak by ~15% in post-AMI HF.
Why the study?
The study evaluated the effect of adding cardiac rehabilitation to sacubitril/valsartan in patients with heart failure after acute myocardial infarction.
Does sacubitril/valsartan combined with cardiac rehabilitation improve cardiorespiratory fitness and cardiac remodeling in patients with heart failure after acute myocardial infarction?
RCT (n=118)
Double-blind
1:1
No
Does sacubitril/valsartan combined with cardiac rehabilitation improve cardiorespiratory fitness and cardiac remodeling in patients with heart failure after acute myocardial infarction?
In patients with heart failure following acute myocardial infarction, combining sacubitril/valsartan with cardiac rehabilitation significantly improves cardiorespiratory fitness and left ventricular ejection fraction compared to sacubitril/valsartan alone.
Answers are grounded in this paper and cite their sources.
Supports adding cardiac rehabilitation to sacubitril/valsartan in post-AMI HF; extends mixed sac/val data for LVEF.
OBJECTIVE: To investigate the effect of sacubitril/valsartan (ARNI) combined with cardiac rehabilitation (CR) in patients with heart failure (HF) after acute myocardial infarction (AMI). METHODS: A total of 118 patients with HF after AMI were screened and randomly divided into an experimental group and a control group. The control group was given ARNI. The experimental group received CR treatment in addition to the control treatment. The primary endpoint was cardiorespiratory fitness as measured by the cardiopulmonary exercise test (CPET). The secondary endpoints included cardiac remodeling detected by NT-ProBNP and cardiac ultrasound. All participants were assessed by CPET, NT-ProBNP, and cardiac ultrasound at baseline and after treatment. RESULTS: peak), and metabolic equivalents (METs) in the experimental group were significantly greater than those in the control group (all P < 0.05). However, there was no significant difference in BNP, Left atrial diameter (LA) or Left ventricular end diastolic diameter (LVD) between the two groups (P > 0.05). CONCLUSIONS: Patients with HF after AMI could benefit from combined ARNI and CR. TRIAL REGISTRATION: http://www.chictr.org.cn , ChiCTR2400093772 (11/12/2024). Retrospectively registered.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) conducted an RCT in Heart failure after acute myocardial infarction (n=118). Sacubitril/valsartan combined with cardiac rehabilitation vs. Sacubitril/valsartan alone was evaluated on VO2 peak (ml/min/kg) at 3 months (p=0.002). Sacubitril/valsartan combined with cardiac rehabilitation improved VO2 peak compared to sacubitril/valsartan alone in patients with HF after AMI.
Synapse has enriched 10 related papers. Consider them for comparative context: